AXIN1

AXIN1 Full Name

axin 1

AXIN1 Introduction

AXIN1 (Axis Inhibition Protein 1) is a multifunctional scaffold protein encoded by the AXIN1 gene and is widely recognized as a central negative regulator of the canonical Wnt/β-catenin signaling pathway. For researchers investigating cancer biology, developmental disorders, or signaling-related therapeutic targets, AXIN1 represents a critical molecular checkpoint because abnormal AXIN1 activity can disrupt cellular homeostasis and promote uncontrolled gene expression. As a key component of the β-catenin destruction complex, AXIN1 interacts with APC, GSK-3β, CK1, and β-catenin to facilitate β-catenin phosphorylation and subsequent ubiquitin-mediated degradation. Beyond its classical role in Wnt suppression, recent studies have demonstrated that AXIN1 functions as a versatile signaling hub involved in Hippo, TGF-β, AMPK, mTOR, MAPK, and oxidative stress response pathways, highlighting its broader importance in coordinating cellular proliferation, metabolism, differentiation, and stress adaptation.

The biological function of AXIN1 is primarily determined by its ability to act as a molecular scaffold that assembles signaling complexes and regulates protein modification events. Through its regulator of G-protein signaling (RGS) domain and other functional regions, AXIN1 controls the spatial organization and activity of multiple kinases and regulatory proteins, enabling precise phosphorylation-dependent signaling regulation. Recent research has proposed the concept of an AXIN1-associated phosphorylation complex (AAPC), suggesting that AXIN1 actively coordinates kinase–substrate interactions rather than simply serving as a passive inhibitor of Wnt signaling. Post-translational modifications, including acetylation and deacetylation, further influence AXIN1 stability and activity. For example, SIRT4-mediated deacetylation of AXIN1 has been shown to regulate β-catenin degradation dynamics, revealing an additional layer of control in Wnt pathway activation and providing new insights into how signaling abnormalities emerge in disease states.

Dysregulation of AXIN1 is strongly associated with human diseases, particularly cancer, where loss-of-function mutations, reduced protein stability, or impaired AXIN1-mediated signaling control can contribute to tumor development. Somatic mutations in AXIN1 have been identified in hepatocellular carcinoma and other malignancies, often resulting in excessive β-catenin accumulation and activation of oncogenic transcription programs. Studies in liver cancer models have shown that AXIN1 disruption enhances Wnt/β-catenin signaling, while restoration or stabilization of AXIN activity may represent a potential therapeutic strategy. In gastric cancer, abnormal activation of the E3 ubiquitin ligase TRIM11 promotes tumor progression by destabilizing AXIN1 protein, leading to increased β-catenin pathway activity and enhanced cancer cell migration. Because AXIN1 regulates multiple interconnected signaling networks, targeting AXIN1 stability, protein interactions, or downstream pathway dependencies is being explored as a promising approach for developing precision therapies against Wnt-driven cancers and other AXIN1-related disorders.

Alternate Names for AXIN1

AXIN1; axin 1; axin-1; PPP1R49; protein phosphatase 1; regulatory subunit 49; axis inhibitor 1; fused, mouse, homolog of; axis inhibition protein 1; protein phosphatase 1, regulatory subunit 49; AXIN; MGC52315;

• 1.Qiu L, et al.; The scaffold protein AXIN1: gene ontology, signal network, and physiological function. Cell Commun Signal. 2024 Jan 30;22(1):77.
  2.Wang Y, et al.; SIRT4-Catalyzed Deacetylation of Axin1 Modulates the Wnt/β-Catenin Signaling Pathway. Front Oncol. 2022 May 30;12:872444.